Search Results
Jan 13, 2026, 21:12 ET JAPAN SUI COLLECTION à Kyoto : apporter au monde l'essence de la beauté et des traditions japonaises -- Rapport sur l'événement organisé par la State Guest House de Kyoto
https://drive.google.com/file/d/1Pq5DhrSmhl6kl3pandogP8juYX-LfzrJ/view?usp=sharing Spectacles et gastronomieUn défilé de mode de JUNKO KOSHINO et une représentation de théâtre
More news about: Cabinet Office, Government of Japan
Jan 08, 2026, 08:00 ET Klotho Neurosciences to Present at the Biotech Showcase 2026
development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease,
More news about: Klotho Neurosciences, Inc.
Jan 07, 2026, 01:00 ET JAPAN SUI COLLECTION in Kyoto: Bringing Essence of Japanese Beauty and Tradition to World -- Report on Kyoto State Guest House Event
https://drive.google.com/file/d/1Pq5DhrSmhl6kl3pandogP8juYX-LfzrJ/view?usp=sharing Performances & CuisineA fashion show by JUNKO KOSHINO and a traditional "kyogen" comic
More news about: Cabinet Office, Government of Japan
Jan 07, 2026, 01:00 ET JAPAN SUI COLLECTION in Kyoto: Bringing Essence of Japanese Beauty and Tradition to World -- Report on Kyoto State Guest House Event
https://drive.google.com/file/d/1Pq5DhrSmhl6kl3pandogP8juYX-LfzrJ/view?usp=sharing Performances & CuisineA fashion show by JUNKO KOSHINO and a traditional "kyogen" comic
More news about: Cabinet Office, Government of Japan
Jan 05, 2026, 04:30 ET 第六項BTD！蘆康沙妥珠單抗(sac-TMT)聯合免疫療法K藥一線治療PD-L1陽性NSCLC獲突破性療法認定
作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型TROP2 ADC，針對NSCLC、BC、胃癌(GC)、婦科腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)采用新型連接子進行開發，其通過偶聯一種貝洛替康衍生的拓撲異構酶I抑制劑作為有效載荷，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞並於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞周期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。
More news about: 科倫博泰
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
Dec 17, 2025, 16:11 ET Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.4Vahratian A, Briones EM, Jamal A, Marynak KL. Electronic cigarette use among adults in the United States, 2019–2023. NCHS Data Brief, no 524. Hyattsville, MD: National Center for Health Statistics.
More news about: Achieve Life Sciences
Dec 08, 2025, 09:00 ET Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
1997 Sep;62(3):471-8. https://pubmed.ncbi.nlm.nih.gov/9272652/ ii Breymeyer KL, et al. Subjective mood and energy levels of healthy weight and overweight/obese healthy adults on high-and low-glycemic load experimental diets. Appetite.
More news about: Abbott
Dec 07, 2025, 01:09 ET 喜訊！科倫博泰佳泰萊®、達泰萊®、科泰萊®成功納入2025國家基本醫保目錄
NPC的第二項適應症獲批上市，是全球首個獲批一線治療NPC的PD-L1單抗。上述兩項適應症均被納入2025年版國家基本醫保目錄。塔戈利單抗單藥在經二線及以上治療的R/M NPC患者中展現出了良好的療效與安全性，研究結果顯示：截至2022年1月13日，塔戈利單抗單藥治療的ORR為26.5%，中位PFS為2.8個月，中位OS為15.3個月，並且患者整體安全性良好、可控。KL167-Ⅲ-08研究進一步驗證了其在R/M NPC患者一線治療中的臨床應用價值，研究結果顯示：（１）截至2024年2月4日，與化療相比，塔戈利單抗聯合順鉑和吉西他濱一線治療復發或轉移性鼻咽癌可獲得更優的PFS、更高的ORR和更長的DoR，且無論患者PD-L1表達如何，均可獲益；
More news about: 科伦博泰
Dec 03, 2025, 22:20 ET NEXTDC、日本の中心部に次世代AI対応プラットフォームTK1 Tokyoを開設し、国際展開を加速
スケーラー、クラウド・プラットフォーム、防衛組織、企業が、日本の中核的なビジネス拠点と人口密集地の近くに、遅延の影響を受けやすい高密度のワークロードを展開できるようになります。また、地域全体で一貫した運用の卓越性、回復力、セキュリティを確保できるようになります。TK1 Tokyoは、KL1 Kuala Lumpurなどの大規模開発に続く、NEXTDC のマルチマーケット拡大戦略の一環です。同社は、アジア太平洋地域全体のAIの進展、クラウド移行の加速、国家デジタル・インフラストラクチャ需要の増加を原動力とする画期的な成長期に向けて態勢を整えています。着工が完了し、現在工事が進行中で、2030年後半の運用開始を目指しているTK1
More news about: NEXTDC
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 25, 2025, 17:31 ET Mitochondrial Myopathies Market to Register Stunning Growth at a CAGR of 26.5% During the Forecast Period (2025-2034) Driven by Recent Approvals and Pipeline Advancements and Rising Awareness | DelveInsight
KYGEVVI, improved diagnosis, and rising awareness. Additionally, the expected launch of therapies such as Sonlicromanol (Khondrion; redox modulator), KL1333 (Pharming; NAD?/NADH modulation), Zagociguat (Tisento/Cyclerion; sGC stimulation), TTI-0102 (Thiogenesis; thiol-based mitochondrial support), and
More news about: DelveInsight Business Research, LLP
Nov 24, 2025, 07:00 ET Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 19, 2025, 02:30 ET Workday Expands Its Open Ecosystem with New Global Developer Network and Google BigQuery Partnership
extensions to advanced agents. Workday is partnering with universities around the world, including Chennai Institute of Technology and KL University, as well as staffing partners such as Consultnet, Helios Consulting, and Randstad Digital, to offer dedicated training paths and certifications.
More news about: Workday Inc.
Nov 09, 2025, 20:55 ET Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 07, 2025, 10:03 ET Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
this recognition for its pioneering work developing transformative gene and cell therapies using a patented, secreted form of the human Klotho gene (s-KL) to address devastating neurodegenerative and age-related diseases, including ALS, Alzheimer's disease, and Parkinson's disease. By targeting the underlying
More news about: Klotho Neurosciences, Inc.
Nov 04, 2025, 05:46 ET 24 million new wishes added in just one month to GoWish shows what we want under the Christmas tree: Digital cameras are trending like its the year 2000
https://news.cision.com/gowish/i/gowish-onskeskyen-app-store-2025-11-03-kl-21-40-35,c3484296
More news about: GoWish
Nov 04, 2025, 05:44 ET 24 million new wishes added in just one month to GoWish shows what we want under the Christmas tree: Digital cameras are trending like its the year 2000
https://news.cision.com/gowish/i/gowish-onskeskyen-app-store-2025-11-03-kl-21-40-35,c3484296
More news about: GoWish
Nov 03, 2025, 11:00 ET NBA TAKE-TWO MEDIA UNVEILS NEW NBA 2K LEAGUE
Basketball Association (NBA) and Take-Two Interactive Software (NASDAQ: TTWO), today announced the arrival of the newly re-launched NBA 2K League (2KL). The new 2KL is an innovative entertainment property where competition meets culture, bringing everyone from fans to NBA players and creators together to
More news about: NBA Take-Two Media
Oct 27, 2025, 00:00 ET KLN獲西門子醫療委任為香港「即時診斷」解決方案獨家分銷商
* 僅就持續經營業務而言 關於 KL N Medical Limited KLN Medical 致力推動香港及東南亞地區的醫療發展，提供創新醫療科技，提升病人治療成效。憑藉與多個國際知名品牌的合作，KLN Medical
More news about: 嘉里物流聯網有限公司
Oct 26, 2025, 03:53 ET WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
passed FDA on-site inspections with no single observation. By the end of 2025, total reactor volume of small molecule APIs is expected to reach over 4,000kL. In September 2025, the construction of peptide capacity in Taixing was completed ahead of schedule; the Company's total reactor volume of Solid Phase
More news about: WuXi AppTec
Oct 24, 2025, 18:32 ET Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
https://www.ncbi.nlm.nih.gov/books/NBK431049/9 Hackett KL, et al. Arthritis Care Res (Hoboken). 2012;64(11):1760-1764.10 Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg
More news about: Johnson & Johnson
Oct 20, 2025, 22:31 ET MAY ZHOU, Chairwoman of School Board of KL International School of Chongqing Bashu: A Decade of Dedication -- "A Responsive School for A Changing World"
CHONGQING, China, Oct. 20, 2025 /PRNewswire/ -- In 2015, KL International School of Chongqing Bashu (KLIS) was officially established, introducing authentic American education to Southwest China. Over the
More news about: KL International School of Chongqing Bashu
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
2021;8(4):1637-1649. doi:10.1007/s40744-021-00357-1 Zhao SS, Kearsley-Fleet L, Bosworth A, Watson K; BSRBR-RA Contributors Group, Hyrich KL. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. Rheumatology (Oxford). 2022;61(12):4678-4686.
More news about: AbbVie
Oct 20, 2025, 04:57 ET The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.